Persistent Varicella Transmission in a High-Coverage Single-Dose Vaccination Program: Costa Rica, 2015–2024
Authors:
- Oscar Hidalgo-MoraOHOscar Hidalgo-Mora
- Helena Brenes-ChacónHBHelena Brenes-Chacón
- Sebastián Ospina-HenaoSOSebastián Ospina-Henao
- Alejandra Soriano-FallasASAlejandra Soriano-Fallas
- Gabriela Naranjo-ZuñigaGNGabriela Naranjo-Zuñiga
- Gabriela Ivankovich-EscotoGIGabriela Ivankovich-Escoto
- María L. Ávila-AgüeroMaría L. Ávila-Agüero
Preprint
- 15 September 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Costa Rica introduced universal one-dose varicella vaccination in 2007. Although the disease burden subsequently declined, varicella cases and hospitalizations continue to be reported. We characterized varicella epidemiology and healthcare burden in Costa Rica using the most recent nationally available data. Methods: We conducted a nationwide retrospective descriptive study using aggregated surveillance and ad-ministrative data from the Ministry of Health and the Costa Rican Social Security Fund. Outcomes included notified incidence (2015–2022), outpatient and emergency department visits (2019–2024), hospitalizations (2015–2024), in-hospital deaths associated with varicella (2018–2020), reported institutional outbreaks, and first-dose vaccination coverage (2018–2024). Results: Between 2015 and 2022, incidence declined by 84% in males and 83% in females, although it increased until 2019 and declined markedly during the COVID-19 pandemic. Infants and children aged 1–9 years accounted for the largest proportion of reported cases. Among 354 hospitalizations, adults aged 20–44 years accounted for 30.5%. Comparing 2015–2018 with 2021–2024, hospitalizations declined by approximately 56% among chil-dren aged < 4 years and increased by approximately 200% among adults aged 20–44 years. Three varicel-la-associated in-hospital deaths, all in adults, and one institutional outbreak were identified. First-dose coverage averaged approximately 92% during 2018–2022 and exceeded 95% in 2023–2024. Conclusions: Despite substantial reductions in reported incidence, varicella circulation and healthcare burden persist, with hospitalizations increasingly concentrated among adults. These findings support sustaining high first-dose coverage, strengthening surveillance, and evaluating the potential contribution of a two-dose vac-cination strategy.Keywords
All Related Versions
- Version 1, 2026-09-15, Preprints
- Published version: Vaccines, 14 (10), 909.
This publication has 22 references indexed in Scilit:
- Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, BrazilVaccine, 2022
- Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countriesVaccine, 2021
- Impact of the tetra viral vaccine introduction on varicella morbidity and mortality in the Brazilian macro regionsJornal de Pediatria, 2019
- Global impact of varicella vaccination programsHuman Vaccines & Immunotherapeutics, 2018
- Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in BrazilVaccine, 2018
- Varicella epidemiology in Latin America and the CaribbeanExpert Review of Vaccines, 2017
- Varicella prevention in Costa Rica: impact of a one-dose schedule universal vaccinationExpert Review of Vaccines, 2016
- Varicella zoster virus related deaths and hospitalizations before the introduction of universal vaccination with the tetraviral vaccineJornal de Pediatria, 2016
- Varicella zoster virus infectionNature Reviews Disease Primers, 2015
- Impact of Varicella Vaccination on Health Care UtilizationJAMA, 2005